Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis

Cystic fibrosis is an inherited condition, associated with mutation of a specific gene involved in the movement of salt across cells. One of the proposed treatments that targets a particular type of this mutation is a drug called Ataluren, which was the subject of a new Cochrane Review in January 2017. One of the authors, Kevin Southern from the Department of Women's and Children's Health at the University of Liverpool in the UK, describes the available evidence in this podcast.

Source: Podcasts from The Cochrane Library - May 23, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts